Table 5 Desirability of MRDT proposals to promote R&D for neglected diseases
From: Expert Delphi survey on research and development into drugs for neglected diseases
| Â | Â | % (n) | % (n) | % (n) | % (n) | % (n) | Â | Â |
|---|---|---|---|---|---|---|---|---|
| Â | Â | very desirable | desirable | undesirable | very undesirable | no judgment | Total valid % (n) | Total N (Missing) |
Prize funds with prizes awarded based on degree of innovation | Round I | 35.6% (42) | 44.1% (52) | 6.8% (8) | 3.4% (4) | 10.2% (12) | 118 | 159 (41) |
| Â | Round II | 33.9% (19) | 35.7% (20) | 12.5% (7) | 3.6% (2) | 14.3% (8) | 56 | 77 (21) |
Obligation for national governments to invest into neglected disease R&D | Round I | 48.3% (56) | 38.8% (45) | 6.9% (8) | 1.7% (2) | 4.3% (5) | 116 | 159 (43) |
| Â | Round II | 40.4% (23) | 36.8% (21) | 14.0% (8) | 1.8% (1) | 7.0% (4) | 57 | 77 (20) |
Separation of innovation incentives from drug prices | Round I | 38.8% (45) | 30.2% (35) | 4.3% (5) | 4.3% (5) | 22.4% (26) | 116 | 159 (43) |
| Â | Round II | 38.2% (21) | 27.3% (15) | 12.7%(7) | 5.5% (3) | 16.4% (9) | 55 | 77 (22) |